| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H17BrCl2FN3O5S |
| Molecular Weight | 629.282 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)NS(=O)(=O)C1=CC=C(NC(=O)CC2=C(F)C(OC3=CC(Cl)=CC(=C3)C#N)=C(Br)C=C2)C(Cl)=C1
InChI
InChIKey=ULTDEARCBRNRGR-UHFFFAOYSA-N
InChI=1S/C24H17BrCl2FN3O5S/c1-2-21(32)31-37(34,35)17-4-6-20(19(27)11-17)30-22(33)9-14-3-5-18(25)24(23(14)28)36-16-8-13(12-29)7-15(26)10-16/h3-8,10-11H,2,9H2,1H3,(H,30,33)(H,31,32)
| Molecular Formula | C24H17BrCl2FN3O5S |
| Molecular Weight | 629.282 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
R-1206 (also known as Elsulfavirine) is a phenylacetamide derivative patented by Roche Palo Alto LLC as non-nucleoside reverse transcriptase inhibitor (NNRTI) for treating retroviral infections. R-1206 is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. The antiviral activity of R-1206 is broad, with activity demonstrated towards various viral strains and clinical isolates of HIV, including those resistant to other NNRTIs. Furthermore, R-1206 was associated with a low probability of cross-resistance or resistance development, and a high genetic barrier to the development of resistant drug mutations. In clinical trials, R-1206 20 and 40 mg demonstrated superiority to efavirenz in terms of the effectiveness to reduce the level of viral load to 400 copies/mL after 12 weeks of therapy. R-1206 20 mg once daily is generally well tolerated in ART-naive HIV-1 infected patients.
